Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis

计划入组 115 人 · 首次发布于 2025 年 4 月 18 日

Low Dose Heparin Factorial Trial

计划入组 800 人 · 首次发布于 2022 年 10 月 24 日

An Unblinded, Single Arm, Pilot Observational Study to Test the Safety, Tolerability, Immunogenicity and the Biological Effects of TRB-001 Vaccination.

计划入组 6 人 · 首次发布于 2026 年 8 月 20 日

TRB-061

TRB-4

TRB-012

TRB CHEMEDICA

France

TRB Chemedica AG

Germany

TRB KEMEDIKA INTERNESHNL S.A., PREDSTAVITELSTVO

Russia

Transpire Bio Receives FDA Orphan Drug Designation for Inhaled Therapies Targeting IPF and Glioblastoma

US Orphan Drug Market Poised to Exceed $190 Billion by 2030 as FDA Designations Accelerate Rare Disease Therapy Development

TRexBio Initiates First-in-Human Trial of TRB-061, Novel TNFR2 Agonist for Atopic Dermatitis